U.S. Markets closed

Akers Biosciences, Inc. (AKER)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.98+0.47 (+8.53%)
At close: 4:00PM EDT

5.96 -0.02 (-0.33%)
After hours: 7:52PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.51
Open5.50
Bid6.01 x 1300
Ask6.05 x 800
Day's Range5.34 - 6.09
52 Week Range1.55 - 16.32
Volume1,391,678
Avg. Volume1,214,759
Market Cap36.628M
Beta (5Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Hedge Funds Are Nibbling On Akers Biosciences Inc (AKER)
    Insider Monkey

    Hedge Funds Are Nibbling On Akers Biosciences Inc (AKER)

    At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

  • TheStreet.com

    Microcap Akers Biosciences Spikes on Covid-Vaccine Progress

    Akers and Premas Biotech are three steps into a four-step plan that could lead to clinical trials of a vaccine candidate.

  • Akers Biosciences plans $4.6M stock sale, advances COVID-19 vaccine candidate
    American City Business Journals

    Akers Biosciences plans $4.6M stock sale, advances COVID-19 vaccine candidate

    Akers Biosciences Inc., a South Jersey medical device company that recently joined the race to develop a COVID-19 vaccine, plans to raise $4.6 million in a public stock sale. The Thorofare-based company is selling 766,667 shares of its common stock at a purchase price of $6.00 per share, according to documents filed with the Securities and Exchange Commission. Last month, Akers entered into an in-licensing and product development deal for a coronavirus vaccine candidate under development by Premas Biotech.